Sangamo Therapeutics
501 Canal Boulevard
Suite F
Richmond
California
94804
United States
Tel: 510-970-6000
Fax: 510-970-7890
Website: http://www.sangamo.com/
About Sangamo Therapeutics
Sangamo Therapeutics is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has open Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington's disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.
557 articles with Sangamo Therapeutics
-
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences - Nov 05, 2020
11/5/2020
Sangamo Therapeutics, Inc., a genomic medicine company, announced that management will present at the following investor conferences:
-
Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results
11/4/2020
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter 2020 financial results and recent business highlights
-
Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast
10/28/2020
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2020 financial results after the market closes on Wednesday, November 4, 2020. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its fina
-
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment
10/7/2020
Pfizer Inc. and Sangamo Therapeutics, Inc., a genomic medicines company, announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec, an investigational gene therapy for hemophilia A patients.
-
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences - Sep 28, 2020
9/28/2020
Sangamo Therapeutics, Inc., a genomic medicine company, announced that management will present at the following investor conferences
-
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences - Sep 02, 2020
9/2/2020
Sangamo Therapeutics, Inc., a genomic medicine company, announced that management will present at the following investor conferences
-
Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
8/10/2020
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present at the 2020 Wedbush PacGrow Healthcare Conference on August 12, 2020 at 2:55 p.m. Eastern Time. The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations . About S
-
Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results
8/5/2020
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial results and recent business highlights.
-
Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders
7/30/2020
Collaboration for gene regulation therapies for three neurodevelopmental targets, including for genes linked to autism spectrum disorder and intellectual disability
-
Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast
7/29/2020
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2020 financial results after the market closes on Wednesday, August 5, 2020.
-
The Brisbane, California-based company announced its plans to separate the two units and treat them as individual operations with individual managers.
-
Sangamo Announces R&D Organization Changes
6/24/2020
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization. Going forward, research and development will each be managed as separate functions. A search for a Head of Development is underway. Jason Fontenot, Senior Vice President, Cell Therapy, will assume the role of Interim Head of Research. The heads of research and development will report to CEO Sandy Macrae.
-
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
6/18/2020
Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525, or PF-07055480), an investigational gene therapy for patients with severe hemophilia A
-
Pfizer and Sangamo Therapeutics released follow-up data from its Phase I/II Alta study in hemophilia A that showed an investigational gene therapy treatment provided blood-clotting activity levels for more than one year.
-
Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference
5/29/2020
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:00 p.m. ET. The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations . About Sangamo Therapeutics Sangam
-
Sangamo Therapeutics Announces Participation at the Bank of America 2020 Health Care Conference
5/12/2020
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Bank of America 2020 Health Care Conference on Thursday, May 14 at 4:20 p.m. ET. The audio presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations . About Sangamo Therapeutics
-
Sangamo Therapeutics Reports Business Highlights and First Quarter 2020 Financial Results
5/11/2020
Sangamo Therapeutics, Inc., a genomic medicine company, reported first quarter 2020 financial results and recent business highlights.
-
Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting
5/7/2020
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that it is changing its 2020 Annual Meeting of Stockholders to a virtual-only format due to public health and safety concerns related to the coronavirus (COVID-19) pandemic.
-
Sangamo Therapeutics Announces First Quarter 2020 Conference Call and Webcast
5/4/2020
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2020 financial results after the market closes on Monday, May 11, 2020.
-
Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy
4/28/2020
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 12th to May 15th, 2020, in a virtual format.